Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational, retrospective, case series study of factor VIII inhibitor bypassing activity (FEIBA) for factor Xa (FXa) inhibitor reversal for apixaban and rivaroxaban in patients with acute intracranial and nonintracranial hemorrhage

Next Previous
X
Search
Trial Profile

An observational, retrospective, case series study of factor VIII inhibitor bypassing activity (FEIBA) for factor Xa (FXa) inhibitor reversal for apixaban and rivaroxaban in patients with acute intracranial and nonintracranial hemorrhage

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Factor VIII inhibitor bypassing fraction (Primary)
  • Indications Haemophilia; Intracranial haemorrhages
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Apr 2021 New trial record
    • 10 Apr 2021 Primary endpoint (effectiveness of FEIBA to achieve excellent or good (collectively defined as effective) hemostasis for acute ICH and non-ICH bleeding events secondary to apixaban or rivaroxaban at the doses utilized) has not been met.
    • 10 Apr 2021 Results published in the Annals of Pharmacotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top